<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01942174</url>
  </required_header>
  <id_info>
    <org_study_id>9144</org_study_id>
    <nct_id>NCT01942174</nct_id>
  </id_info>
  <brief_title>VACcination In Methotrexate Treated Rheumatoid Arthritis Patients</brief_title>
  <acronym>VACIMRA</acronym>
  <official_title>Lead Time of the Methotrexate Establishment and Vaccinal Protection Against the Pneumococcal Agent in Patients Affected With Rheumatoid Polyarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>APHP (Hospital Cochin)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To estimate the rate of immunological answer 1 month after antipneumococcal vaccination by
      the conjugated vaccine Prevenar13 ® in patients suffered from rheumatoid polyarthritis and
      who begin a treatement by methotrexate either in the same time, either 1 month later.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients suffering from rheumatoid polyarthritis have an increased risk to develop an
      infection compared to general population, with a more important mortality risk because
      pneumococcus is considered as one of the major pathogenic agents. Antipneumcoccal vaccination
      is recommended to patients suffering from chronic inflammatory rheumatism treated with
      immunosuppressants. Methotrexate is a long term treatment used in first intention for
      rheumatoid polyarthritis. A recent study shows a decrease of efficacity of antipneumoccal
      vaccination for patients suffering from rheumatoid polyarthritis treated by methotrexate. The
      tested hypothesis will be the presence of better vaccinal protection for patients suffered
      from rheumatoid polyarthritis after 1 month between antipneumococcal vaccination and the
      initiation of methotrexate. The objective is to compare immunologic response for
      antipneumococcal vaccination between patients who are vaccinated in the same time of
      initiation of methotrexate and patients who are vaccinated 1 month before the beginning of
      the treatment.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 27, 2013</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Actual">August 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>rate of immunological positive answer 1 month after antipneumococcal vaccination by the conjugated vaccine Prevenar13 ® in patients suffering from rheumatoid polyarthritis.</measure>
    <time_frame>1 month</time_frame>
    <description>Patient who begins a treatement by methotrexate either in the same time, either 1 month later.
An answer will be considered as positive if the patient answers in at least 3 on 5 of interest serotypes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients in each group who will know fully immunological answer to 5 interest serotypes after the first antipneumococcal vaccination (Prevenar13)</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients in each group who will know an immunological answer to 13 serotypes after the first antipneumococcal vaccination (Prevenar13)</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients who will know a fully immunological answer (13 serotypes of vaccine) after a antipneumococcal revaccination with Pneumo 23.</measure>
    <time_frame>3, 6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients who will suffer from adverse events in relation with the antipneumococcal vaccination</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of occurence of disease spurts from the first vaccination until the end of the study</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>occurence of the pneumococcal disease from the first vaccination to the end of the study.</measure>
    <time_frame>1, 6, 7 and 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">276</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Immediate group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>For these patients, the methotrexate treatment is initiated in the same time that the antipneumococcal vaccination by Prevenar13. A revaccination by Pneumo23/Pneumovax is administred 2 months after the first vaccination.
Interventions : biological/vaccine and drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>period group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Methotrexate treatment is initiated 1 month later the first antipneumococcal vaccination by Prevenar13.
A revaccination by Pneumo23/Pneumovax is administred 2 months after the first vaccination
Interventions : biological/vaccine and drug</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Prevenar 13</intervention_name>
    <description>Vaccination at the beginning of the study (day 0)</description>
    <arm_group_label>Immediate group</arm_group_label>
    <arm_group_label>period group</arm_group_label>
    <other_name>Antipneumococcal vaccination</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pneumo23 / Pneumovax</intervention_name>
    <description>Vaccination 2 months later the beginning of the study NB : Vaccine Pneumo23 has been replaced by equivalent vaccine Pneumovax in September 2017 because of the stop of commercialization of Pneumo23 in France by the pharmaceutical company</description>
    <arm_group_label>Immediate group</arm_group_label>
    <arm_group_label>period group</arm_group_label>
    <other_name>Antipneumococcal vaccination</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate - Immediate</intervention_name>
    <description>concerning immediate group, methotrexate is Initiated in the same time that the antipneumococcal vaccination by prevenar 13</description>
    <arm_group_label>Immediate group</arm_group_label>
    <other_name>conventional methotrexate treatment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate - Delay</intervention_name>
    <description>For &quot;period group&quot;, methotrexate is Initiated &amp; month after the antipneumococcal vaccination by prevenar 13</description>
    <arm_group_label>period group</arm_group_label>
    <other_name>Experimental methotrexate treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult (&gt;18 yeas old) suffers from rheumatoid arthritis considering ACR/EULAR 2010
             criteria

          -  Rheumatoid arthritis considering 3,2&lt;DAS&lt;5,1

          -  Patient did not treat by long term treatment or has stopped a treatment by
             sulfasalazine, hydroxychloroquine or methotrexate for at least 3 months

          -  Patient has never treated by biotherapy

          -  Patient has never vaccinated against pneumococcal

          -  Patient has signed study consent form

        Exclusion Criteria:

          -  Patient has ever treated by leflunomide or has treated previously by leflunomide (last
             3 months)

          -  Patient is currently treated by methotrexate or has treated previously by methotrexate
             (last 3 months)

          -  Contraindication to methotrexate: renal insuffisance, alcoolic, chronic hepatisis,
             infectious condition, AIDS, hematological failure (cytopeny), pregnancy, obesity,
             diabet, respiratory disease, gastric ulcer

          -  Contraindication to corticotherapy

          -  Pregnancy or pregancy wish

          -  Nursing

          -  Absence of oral contraception for women of childbearing age

          -  Patient of age protected by law et deprived of liberty

          -  Subject who refuses to be vaccinated against pneumococcis agent

          -  Previous history of vaccination allergy (anaphylactic shok, Quincke oedema...)

          -  Gluten hypersensivity or intolerance

          -  Other vaccination during the last month before inclusion

          -  Ig perfusion during the last 3 months period before the study inclusion or during the
             study duration

          -  Patient currently treated by anticoagulant or has not been stopped for at least 48h
             before the study inclusion or hemostasis failure which is contraindicated with
             muscular injection

          -  Participation with an other clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacques MOREL, PU-PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Montpellier</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Nord</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU La Cavale Blanche</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Montpied</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Bicetre</name>
      <address>
        <city>Le Kremlin Bicetre</city>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Du Mans</name>
      <address>
        <city>Le Mans</city>
        <zip>72000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Dupuytren</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU La Conception</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Montpellier - Hôpital Lapeyronie</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nice - Hôpital L'Archet 1</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Carémeau</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Orléans - Hôpital La Source</name>
      <address>
        <city>Orléans</city>
        <zip>45000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Saint Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU La Pitié Salpétrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35056</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Bois Guillaume</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Saint Etienne - Hôpital Nord</name>
      <address>
        <city>Saint Etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Purpan</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Trousseau</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHPG Monaco - Hôpital Prince Grace de Monaco</name>
      <address>
        <city>Monaco</city>
        <zip>98000</zip>
        <country>Monaco</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Monaco</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>September 10, 2013</study_first_submitted>
  <study_first_submitted_qc>September 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2013</study_first_posted>
  <last_update_submitted>January 31, 2019</last_update_submitted>
  <last_update_submitted_qc>January 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Antipneumococcal vaccination</keyword>
  <keyword>Methotrexate treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

